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Abstract: Age-related macular degeneration (AMD) is the leading cause of blindness in 
developed countries. The etiology of AMD remains poorly understood and no treatment is 
currently available for the atrophic form of AMD. Atrophic AMD has been proposed to involve 
abnormalities of the retinal pigment epithelium (RPE), which lies beneath the photoreceptor 
cells and normally provides critical metabolic support to these light-sensing cells. Cumulative 
oxidative stress and local inﬂ  ammation are thought to represent pathological processes involved 
in the etiology of atrophic AMD. Studies of tissue culture and animal models reveal that 
oxidative stress-induced injury to the RPE results in a chronic inﬂ  ammatory response, drusen 
formation, and RPE atrophy. RPE degeneration in turn causes a progressive degeneration of 
photoreceptors, leading to the irreversible loss of vision. This review describes some of the 
potential major molecular and cellular events contributing to RPE death and inﬂ  ammatory 
responses. In addition, potential target areas for therapeutic intervention will be discussed and 
new experimental therapeutic strategies for atrophic AMD will be presented.
Keywords: age-related macular degeneration, danger signals, complement, inﬂ  ammation, 
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Introduction
Age-related macular degeneration (AMD) is an idiopathic retinal degenerative disease 
and the cause of irreversible, profound vision loss in people over the age of 60 years 
(Evans and Wormald 1996). Due to a rapidly aging population, the number of people 
with AMD in the US is estimated to increase from 1.75 million in 2000 to 2.95 million 
in 2020 (Friedman et al 2004). Similar proportional increases in the worldwide 
prevalence of AMD can be expected placing an increasing burden on health services. 
The market for AMD therapies is projected to increase from $638 million in 2005 to 
$2722 million in 2015 (Augustin and Offermann 2006).
AMD occurs in two major forms: atrophic (dry) AMD and exudative (wet) AMD. 
Atrophic AMD, characterized by retinal pigment epithelial (RPE) cell atrophy and 
subjacent photoreceptor degeneration, accounts for approximately 25% of cases 
with severe central vision loss (Klein et al 1997). In contrast, exudative AMD is 
characterized by choroidal neovascularization (CNV) through the outer layers of 
Bruch’s membrane under the basement membrane of the RPE or through the RPE 
into the subretinal space with subsequent retinal hemorrhage, detachment, and 
scarring, and accounts for approximately 75% of cases with severe central vision 
loss (Klein et al 1997). These two forms of AMD are both part of the same disease 
process and share similar risk factors for their development. In fact, patients may 
have CNV in one eye and geographic atrophy, the advanced form of atrophic AMD, 
in the second eye. In some cases, the dry form of AMD may progress to wet AMD Journal of Inﬂ  ammation Research 2008:1 50
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(Sunness et al 1999). The speciﬁ  c biological processes that 
determine which form of advanced AMD occurs and why 
and how some of dry AMD later progress to wet AMD are 
still elusive. AMD is an aging-related syndrome caused by 
multiple factors including environmental, nutritional, and 
behavioral (Snodderly 1995; Seddon et al 1996) as well 
as different susceptibilities to these factors based upon an 
individual’s genetic background (Heiba et al 1994; Seddon 
et al 1997). The early pathological changes of atrophic 
AMD begin with extracellular lipid-containing deposits in 
the macular area (Bressler et al 1990). Patients with drusen 
greater than 63 μm in diameter are diagnosed as having early 
AMD (Bird et al 1995; Curcio and Millican 1999). Large 
drusen can merge, become conﬂ  uent and eventually lead 
to geographic atrophy of the central retina. Although the 
vision loss results from photoreceptor damage in the central 
retina and abnormalities of the photoreceptor cells or the 
choroid might contribute to the development of AMD, the 
initial pathogenesis of atrophic AMD has been proposed to 
involve the degeneration of RPE cells (Spraul et al 1996; 
Zarbin 1998). The speciﬁ  c genetic and biochemical mecha-
nisms responsible for RPE degeneration in AMD have not 
been well determined. Recent progress in our understand-
ing of atrophic AMD suggests that inﬂ  ammation initiated 
by RPE cell death and RPE cell inﬂ  ammatory responses 
plays an important role in drusen biogenesis and maybe 
central to the etiology of this disease (Hageman et al 2001; 
Rodrigues 2007).
The RPE is a monolayer of cuboidal cells located 
subjacent to the neural retina (Strauss 2005). The basal 
membrane of the RPE is in contact with Bruch’s membrane, 
a multilayered matrix that separates the RPE from the 
underlying choroidal vasculature. The apical membrane of 
the RPE is intimately associated with the outer segments 
of retinal photoreceptor cells. The major function of RPE 
cells is to support the survival and normal functioning of 
photoreceptors by acting as part of the outer blood-retinal 
barrier to control exchange of nutrients, waste products, ions, 
and gases between the underlying choroidal blood vessels and 
overlying photoreceptors (McBee et al 2001). Additionally, 
the RPE is involved in the shuttling of retinoids required for 
visual pigment synthesis to photoreceptors (Thompson and 
Gal 2003), and in phagocytizing shed photoreceptor outer 
segment (POS) membrane discs for photoreceptor renewal 
(Nguyen-Legros and Hicks 2000). RPE cells also produce 
trophic factors necessary for photoreceptor survival, and 
immunological factors necessary for establishing immune 
privilege of the eye (Tanihara et al 1997; Streilein et al 2002). 
Injury to RPE cells causing failure of these functions may 
contribute to the retinal degeneration observed in AMD. Thus,  
there is considerable interest in elucidating the mechanisms 
responsible for RPE injury that would provide the basis for 
designing new strategies to treat or prevent AMD. In this 
review, the molecular and cellular events involved in RPE 
injury and inﬂ  ammation, and potential therapeutic strategies 
are discussed.
Factors causing RPE cell injury
Oxidative stress
Histological staining with biomarkers of oxidative damage 
has demonstrated widespread oxidative damage in the retinas 
of patients with atrophic AMD and to a lesser extent also 
in the retinas of patients with wet AMD (Shen et al 2007). 
Moreover, intravitreal injection of oxidants results in lipid 
peroxidation and retinal degeneration in animal models 
(Cingolani et al 2006). RPE cells suffer from cumulative 
oxidative stress due to normal physiological activity as well 
as environmental factors (Figure 1). RPE cells generate 
reactive oxygen species (ROS) during phagocytosis 
(Miceli et al 1994). RPE phagocytosis takes up the tips of 
the shed POS that contain high concentrations of radicals, 
photo-damaged proteins and lipids. Some of these oxidative-
damaged proteins and lipids are not completely digested by 
RPE lysosomes and accumulate within RPE cells as a major 
source of the photosensitizer, lipofuscin during RPE aging 
(Kennedy et al 1995). Once irradiated by light, lipofuscin 
produces ROS that damage surrounding tissues (Boulton 
et al 1993). Thus, the unique phagocytic function of RPE 
places an additional oxidative burden on the RPE. This 
is particularly true of RPE cells in the macula, where the 
predominant photoreceptors are cones that have a higher 
energy demand than rods (Perkins et al 2003). Additionally, 
the ratio of photoreceptors to RPE cells in the macula is 
signiﬁ  cantly higher than in the para-macular region or the 
periphery (Dorey et al 1989).
In addition to the physiological oxidative stress, aging 
and pathological conditions can also contribute to oxidative 
damage to macromolecules via a reduction in defense 
mechanisms or an increase in ROS production or both 
(Ames et al 1993). Environmental factors such as cigarette 
smoke (Chan 1998), light exposure (Cruickshanks et al 1993), 
diet, and cataract surgery also enhance ROS generation and 
can increase the risk for AMD. Heavy cigarette smokers have 
signiﬁ  cantly higher risks of AMD (Thornton et al 2005; Cong 
et al 2008). Furthermore, smoking can also cause a reduction 
in retinal and choroidal blood ﬂ  ow (Tamaki et al 1999; Journal of Inﬂ  ammation Research 2008:1 51
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Wimpissinger et al 2004, 2005). The relative contribution 
of these two processes to AMD remains to be determined. 
Cataract surgery to remove the lens increases the amount 
of harmful ultraviolet and blue light reaching the retina. 
Epidemiological studies have revealed an increased risk of 
late AMD in patients with cataract surgery (Klein et al 2002; 
Ho et al 2008). Data analysis of participants of the Rotterdam 
study shows that a history of cataract surgery is linked to an 
increased incidence of atrophic AMD, but no correlation 
with wet AMD was observed (Ho et al 2008).
Recent evidence suggests that genetic factors may 
also contribute to the accumulation of oxidative stress. 
Polymorphisms in the age-related maculopathy susceptibility 
2 gene (ARMS2, also known as LOC387715) were shown 
to be strongly associated with increased risk of AMD. The 
A69S polymorphism shows a strong association with risk of 
AMD (odds ratio [OR] 2.66 for GT heterozygotes and 7.05 
for TT homozygotes) (Kanda et al 2007). A deletion-insertion 
polymorphism (del443ins54) in ARMS2 also causes an 
increased risk in individuals carrying single copy of this allele 
(OR, 2.9) or those that are homozygous (OR, 8.1) (Fritsche 
et al 2008). The ARMS2 gene codes for a hypothetical 
protein of approximately 12 ∼ 13.5 kDa expressed in RPE 
and photoreceptor cells that is associated with the mitochon-
drial outer membrane, leading to the hypothesis that ARMS2 
dysfunction could alter mitochondrial energy metabolism and 
homeostasis, thereby generating ROS (Kanda et al 2007; Frit-
sche et al 2008). Animal studies have also provided genetic 
evidence for a role of oxidative stress in AMD. Deletion of 
the superoxide dismutase 1 (SOD1) gene, the product of 
which is responsible for scavenging superoxide, results in 
mice that develop many of the hallmark features of AMD 
including drusen, RPE atrophy, and CNV (Imamura et al 
2006; Hashizume et al 2008).
The factors described above suggest that oxidative stress 
is particularly signiﬁ  cant in the RPE. Indeed, it has been 
demonstrated that a variety of these oxidative stressors can 
cause RPE cell injury and death in cultured RPE cell lines 
(Lu et al 2006; Qin 2007). Once the protection afforded by 
the antioxidant system has been overwhelmed, dysfunction 
and death of RPE cells can occur. Thus, boosting the 
antioxidant capacity of these cells has the potential to prevent 
or delay AMD progression (Snodderly 1995; Winkler 
et al 1999).
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Figure 1 Conditions that trigger retinal pigment epithelial (RPE) cell injury and subsequent release of damage-associated molecule pattern (DAMP) molecules. RPE cell injury 
is triggered by environmental stress, metabolic stress, and complement attack. Injured or dying RPE cells then produce danger signals that are deﬁ  ned as DAMP molecules. 
Some of these danger signals are intracellular molecules and others are the cleaved products of extracellular components such as extracellular matrix (ECM).
Abbreviations: HMGB1, high mobility group box 1; HSPs, heat-shock proteins; MMPs, matrix metalloproteinases.Journal of Inﬂ  ammation Research 2008:1 52
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Complement-mediated bystander lysis
The activation of complement (McGeer and McGeer 2004) is 
a sophisticated attack system designed to destroy invaders, 
stimulate inﬂ  ammation and assist in the phagocytosis of 
waste materials. A role for the complement pathway in AMD 
was ﬁ  rst recognized through the biochemical characterization 
of the composition of drusen. By histochemical analysis 
and immunocytochemical studies drusen were found to 
contain numerous components of the complement pathway 
including complement activators, inhibitors, activation-
speciﬁ  c complement fragments as well terminal pathway 
components (Hageman et al 2001; Anderson et al 2002). 
Complement cascades consist of the classical, alternative, and 
lectin pathways (Walport 2001). Antibodies are considered 
to be the chief activators of the classical complement 
pathway while molecules, such as lipopolysaccharides, 
activate the alternative complement pathway. Once the 
complement system is fully activated, it proceeds to 
assemble the terminal components (C5b, C6, C7, C8, C9) 
into the lytic macromolecule C5b-9, known as the membrane 
attack complex (MAC) that mediates the destruction of 
the foreign bacteria and viruses. However, if host cells 
are inadequately protected, they may also suffer a MAC 
attack in a process termed bystander lysis. Under normal 
physiological conditions, RPE cells protect themselves 
from complement-mediated bystander lysis, by expressing 
high levels of complement pathway regulators, such as 
complement factor H (CFH) (Chen et al 2007; Wu et al 
2007) and CD46 (McLaughlin et al 2003; Vogt et al 2006) 
that inhibit activation of alternative pathway. However, 
acquisition of functional mutations or dys-regulation of these 
regulators during aging can lead to activation of alternate 
pathway. The Y402H polymorphism in CFH in particular 
has been proposed to be the major risk factor for acquiring 
AMD (Edwards et al 2005; Haines et al 2005; Klein et al 
2005). In addition, CFH-related proteins (CFHR) including 
CFHR1, CFHR2, CFHR3, CFHR4, and CFHR5, which lack 
the complement regulatory activity of CFH can indirectly 
modulate activation of the complement pathway, likely 
via competing with CFH (Jozsi and Zipfel 2008). Deletion 
of CFHR1 and CFHR3 has been reported to be associated 
with decreased risk of AMD. Meta-analysis reveals that 
the ORs are 0.35 and 0.63 for a Caucasian population of 
173 cases and 170 controls in the UK (Hughes et al 2006) 
and a Caucasian population of 780 cases and 265 controls 
in the US (Spencer et al 2008). Similarly, the R32G 
polymorphism in complement factor B (CFB), an activator of 
alternative pathway, is signiﬁ  cantly associated with a reduced 
incidence AMD. In a Caucasian population of 698 cases and 
282 controls evaluated at Medical Centers at Vanderbilt and 
Duke Universities, the R32Q variance was strongly associated 
with reduced risk of AMD (OR, 0.21) after controlling for 
age, the Y402H polymorphism, and smoking (Spencer et al 
2007). A similar result is obtained in the combined Columbia 
and Iowa cohorts with 551 cases and 269 controls (OR 0.32) 
(Gold et al 2006). In contrast, genotyping demonstrated 
that a single nucleotide polymorphism in Complement 
factor 3 (C3) is signiﬁ  cantly correlated with an increased 
risk of AMD (Maller et al 2007; Yates et al 2007; Spencer 
et al 2008). In combined English and Scottish groups with 
a population of 847 cases and 701 controls, the ORs for 
S/F heterozygotes and F/F homozygotes are 1.7 and 2.6, 
respectively (Yates et al 2007).
Together, these observations demonstrate a role for 
complement, particularly the alternative pathway, in the 
development of AMD. Consistent with this notion, it has been 
shown that in vitro, RPE cell synthesis of CFH is downregulated 
by direct hydrogen peroxide challenge (Wu et al 2007) or 
exposure to oxidized POS (Chen et al 2007). Furthermore, light 
exposure activates complement pathways in A2E-loaded RPE 
cells (Zhou et al 2006). Thus, it is reasonable to speculate that 
with aging, increased numbers of RPE cells could be subjected 
to bystander lysis due to oxidative stress-induced activation of 
the complement system. While the alternative pathway seems to 
play the major role in AMD, it was recently reported that mice 
immunized with mouse serum albumin (MSA) adducted with 
carboxylpyrrole, an oxidation fragment of docosahexaenoic 
acid (DHA) develop phenotypes mimicking atrophic AMD 
such as RPE cell lysis and drusen formation (Hollyﬁ  eld et al 
2008), suggesting that the classical pathway may also be 
involved in the development of atrophic AMD.
RPE cell inﬂ  ammatory responses
Drusen biogenesis, in particular soft drusen, is a biological 
marker of atrophic AMD. Protein components of drusen 
include immunoglobulins, complement components, 
acute-phase inﬂ  ammatory response molecules, and major 
histocompatibility complex class II antigens (Johnson 
et al 2000; Mullins et al 2000). Cellular components 
of drusen include RPE debris, lipofuscin, and dendritic 
cells (DCs) (Hageman et al 2001). The mechanisms by 
which drusen is formed are poorly understood. However, 
compelling evidence from a number of laboratories suggest 
that inﬂ  ammatory responses of injured RPE cells serve 
as the initial events in drusen biogenesis (Hageman et al 
2001; Anderson et al 2002). Potential triggers of RPE cell Journal of Inﬂ  ammation Research 2008:1 53
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inﬂ  ammatory responses discussed here include molecules 
derived from necrotic RPE cells, complement attack, and 
oxidized adducts.
Pro-inﬂ  ammatory danger 
molecules: DAMPs
Tissue damage arising from nutrient, oxidative, genomic, or 
mechanical stress is a principal stimulus of inﬂ  ammation. 
Since this inﬂ  ammation occurs without infection, it is deﬁ  ned 
as sterile inﬂ  ammation to distinguish it from pathogen-induced 
inﬂ  ammation. Although the mechanisms that stimulate the 
inﬂ  ammatory response to injured cells remain poorly deﬁ  ned, 
progress has been made recently in our understanding of the 
process. In a fashion similar to defenses against invading 
microorganisms, the innate immune system alerts neighboring 
cells to the imminent danger by reacting to damage signals 
generated from dying cells called damage-associated 
molecular patterns (DAMPs). These signals lead to an 
inﬂ  ammatory response by releasing mediators that dilate 
local vasculature and recruit leukocytes from the blood into 
the tissue. These DAMP molecules can be in general divided 
into two categories, intracellular and extracellular DAMPs, 
based on their origin and mechanism of action. Intracellular 
DAMPs are bioactive mediators of cellular origin that directly 
stimulate cells of the innate immune system. Extracellular 
DAMPs are the cleaved fragments of extracellular components 
generated by enzymes released from dead cells.
As shown in Figure 1, intracellular DAMPs include 
the high mobility group box 1 protein (HMGB1) (Klune 
et al 2008), heat-shock proteins (HSPs) (Chen et al 
1999; Asea et al 2000), S100 proteins (Hofmann et al 1999; 
Foell et al 2007), nucleosomes (Muruve et al 2008), ATP 
(Idzko et al 2007), and uric acid (Martinon et al 2006). 
These molecules are expressed in all cell types. Most 
intracellular DAMPs exhibit a double life. As intracellular 
molecules, they play a role in cell homeostasis, for example 
as calcium binding proteins, chaperones, or chromatin-
stabilizing molecules. Once released into the extracellular 
compartment as a result of cell injury, they become ‘danger’ 
signals which serve to warn other cells and tissues of 
imminent danger by activating innate and pro-inﬂ  ammatory 
immune responses. For example, S100B, a member of the 
S100 family of calcium-binding proteins is a ligand for the 
receptor for advanced glycation endproducts (RAGE) and can 
stimulate expression of vascular endothelial growth factor 
(VEGF), transforming-growth factor-β1 and ﬁ  bronectin in 
RPE cells (Kim et al 2007; Ma et al 2007). Induction of a 
variety of cytokines by intracellular DAMPs in RPE cells 
could contribute to disease progression and potentially the 
conversion of atrophic to wet AMD.
Extracellular DAMPs are generated through the cleavage 
of extracellular matrix molecules such as collagen, hyaluronic 
acid, and heparan sulfate into pro-inﬂ  ammatory fragments 
(Wrenshall et al 1999; Johnson et al 2002; Taylor et al 2004; 
Scheibner et al 2006; Weathington et al 2006). Collagen, 
heparan sulfate, and hyaluronan are major components 
of RPE extracellular matrix that have been shown to be 
expressed in cultured RPE cells (Gross-Jendroska et al 1992; 
deS et al 2001). Degradation of extracellular matrix proteins 
is regulated by matrix metalloproteinases (MMPs), a family 
of zinc-binding, calcium-dependent enzymes (Alexander 
et al 1990). Release of MMPs from necrotic RPE cells 
would be expected to disrupt extracellular matrix, generating 
extracellular DAMPs. However, the extent to which these 
cellular triggers and the extracellular DAMPs that they 
generate contribute to the inﬂ  ammatory response in AMD 
has not yet been addressed.
The detection of danger signals is made by antigen-
presenting cells of the innate immune systems through 
receptors that recognize DAMP molecules. The known 
DAMP receptors include CD14, the NACHT-, LRR-, and 
Pyrin-domain-containing protein-3 (NALP3), P2 receptor, 
RAGE, and toll-like receptors (TLR) (Figure 2). CD14, 
NALP3, and P2 receptors detect HSPs (Chen et al 1999; 
Asea et al 2000), monosodium urate (Martinon et al 2006), 
and extracellular ATP (Idzko et al 2007), respectively. RAGE 
(discussed below) is a multi-ligand receptor for advanced 
glycation end (AGE) product, HMGB1, and S100 proteins 
(Barile and Schmidt 2007). TLRs recognize heparin suﬂ  ate, 
HMGB1, HSP, and hyaluronate (Miyake 2007).
RPE cells make up the first line of defense against 
pathogens by expressing TLRs, which recognize microbial 
motifs. The ligation of TLRs leads to a cascade of events 
that culminates in the production of chemokines, and to 
the production of cytokines that can induce DC maturation. 
RPE cells express almost all TLR iso-forms except TLR-8 
(Kumar et al 2004). While, activation of TLR-2, 4, and 9 
have been demonstrated to result in cytokine production 
when cells are challenged with DAMP molecules in other 
systems (Scheibner et al 2006; Miyake 2007) it remains to 
be addressed whether TLRs have similar roles in mediating 
RPE cell danger responses.
Oxidized adducts
RPE cells are challenged with oxidative stress due to light 
irradiation, high oxygen consumption, and phagocytosis Journal of Inﬂ  ammation Research 2008:1 54
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of photo-bleached POS containing high levels of oxidized 
unsaturated fatty acids and free radicals. Many oxidized 
molecules, which are toxic to RPE cells, accumulate within 
and surround RPE cells with aging. Here we will focus our 
discussion on the relevance of AGE products, oxidized low-
density proteins (oxLDL) and carboxyethyl pyrole (CEP) 
adducts to the etiology of AMD.
AGEs are an heterogeneous group of products derived 
from nonenzymatic glycation and oxidation of amino groups 
of proteins, lipids, and nucleic acids. AGEs accumulate 
during normal aging with their formation being accelerated 
in a setting of oxidative stress and inﬂ  ammation (Schleicher 
et al 1997). There is little or no AGE products detected in 
normal retina, but expression of AGE products increases 
concomitantly with drusen formation and development of 
early atrophic AMD (Howes et al 2004). AGE products 
are also present in RPE lipofuscin, an enzymatically 
nondegradable heterogeneous mixture of numerous 
biomolecules (Schutt et al 2003). With the accumulation of 
AGE products during aging, RAGE, receptors for AGEs, 
are simultaneously induced (Yamada et al 2006). RAGE 
belongs to the immunoglobulin super-family of cell surface 
molecules that are constitutively expressed at very low levels 
in numerous cells, including Muller cells, photoreceptor cells, 
RPE cells, and vascular endothelial cells (Howes et al 2004; 
McFarlane et al 2005; Barile and Schmidt 2007). Cellular 
expression of RAGE increases upon ligand binding thus 
further amplifying cellular activation. In vivo, the levels 
of RAGE are correlated with drusen formation and early 
development of AMD (Howes et al 2004). Additionally, 
induction of AGE formation in vivo leads to the increased 
transcription of inﬂ  ammatory genes in the RPE/choroid 
(Tian et al 2005). In cultured human RPE cells, activation 
of AGE-RAGE pathway stimulates expression of VEGF 
(Ma et al 2007), platelet derived growth factor-b (Handa 
et al 1998), and production of interlukin-8 (IL-8) and 
monocyte chemotactic protein-1 (MCP-1) (also known as 
CCL2) (Bian et al 2001). Moreover in vitro, ligand-dependent 
activation of RAGE can trigger RPE cell death (Howes et al 
2004). Similarly, exposure of RPE cells to AGE-modiﬁ  ed 
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Figure 2 Receptors that sense danger signals released from neighboring injured retinal  pigment epithelial (RPE) cells.   Toll-like receptors (TLRs) and the receptor for AGE 
(RAGE) can detect danger signals released from or generated by dying RPE cells. Once stimulated, TLRs and RAGE activate the transcription factor nuclear factor kappa B (NFkB), 
thereby turning on the transcription of many pro-inﬂ  ammatory genes and consequently inducing an inﬂ  ammatory response.   The DAMP molecules ATP and monosodium urate 
stimulate a pathway that works through Nod-like receptor NACHT, LRR, and PYD containing protein-3 (NALP3) and leads to the production of the proinﬂ  ammatory cytokine 
interleukin-1β (IL-1β) and IL-18.   Those pathways surrounded by dotted lines indicate a current lack of data supporting a functional pathway in RPE cells.
Abbreviations: AGE, advanced glycation endproducts; OxLDL, oxidized low density proteins.Journal of Inﬂ  ammation Research 2008:1 55
RPE inﬂ  ammatory responses and AMD prevention
matrix but not normal matrix triggers RPE cell death (Honda 
et al 2001). These observations suggest that activation 
of the RAGE axis is involved in disease progression and 
potentially in the conversion of atrophic to wet AMD. 
Consistent with this notion, transgenic expression of RAGE 
augmented blood-retinal barrier breakdown and leukostasis, 
accompanied by increased expression of VEGF and ICAM-
1 in the retina in a murine diabetic model (Kaji et al 2007). 
Moreover, these changes were signiﬁ  cantly inhibited by 
systemic administration of a soluble form of RAGE.
Oxidation of LDL generates malondialdehyde lysine 
protein adducts or 4-hydroxynoneal cysteine adducts that are 
the major modiﬁ  cations observed in RPE lipofuscin (Schutt 
et al 2003). OxLDLs have been shown to accumulate in 
Bruch’s membrane in AMD patients (Yamada et al 2008). 
Signiﬁ  cantly, treatment of RPE cells in culture with oxLDL 
alters phagosome maturation (Hoppe et al 2004) and inhibits 
phagocytosis of POS (Hoppe et al 2001), an important RPE 
cell function essential for outer segment renewal and survival 
of photoreceptors. Moreover, exposure of RPE cells to 
oxLDL induces transcriptional alterations in genes related 
to lipid metabolism, oxidative stress, inﬂ  ammation and 
apoptosis (Yamada et al 2008). Consistent with this, ingestion 
of oxidized POS stimulates production of IL-8 and MCP-1 
in cultured RPE cells (Higgins et al 2003). Additionally, as 
oxLDLs are ligands for scavenger receptors expressed on 
macrophages oxLDL accumulation leads to the recruitment 
of macrophages (Kamei et al 2007).
Proteomic analysis of drusen revealed the presence of 
a number of oxidized proteins (Crabb et al 2002). Most 
notable of these is CEP adducts. CEP adducts are uniquely 
generated by the oxidation of docosahexaenoate-containing 
lipids. Interestingly, docosahexaenoate is abundant in 
photoreceptors and is the most oxidizable fatty acid in 
humans (Fliesler and Anderson 1983). Western analysis 
and immunocytochemistry confirmed that CEP adducts 
are more abundant in photoreceptors in AMD than normal 
tissue (Crabb et al 2002; Gu et al 2003). Moreover, CEP 
immunoreactivity as well as autoantibodies to CEP was higher 
in plasma from AMD patients (Gu et al 2003). As previously 
noted, mice immunized with MSA adducted with CEP develop 
an atrophic AMD-like phenotype (Hollyﬁ  eld et al 2008). 
Macrophages are observed in the interphotoreceptor matrix in 
these mice. Additionally, immunized mice ﬁ  x C3 in Bruch’s 
membrane (Hollyﬁ  eld et al 2008). Interestingly, CEP modiﬁ  ed 
human serum albumin was shown to stimulate angiogenesis 
in ex-vivo models and a subretinal injection of MSA-CEP 
exacerbated laser-induced CNV in mice (Ebrahem et al 2006). 
Together, these observations implicate oxidized molecules 
in the perturbation of RPE cell function and inﬂ  ammatory 
responses observed in AMD.
Complement-driven inﬂ  ammation
Activated complement will injure host cells and induce 
inﬂ  ammatory responses under the conditions where loss of 
function mutations or downregulation of inhibitory regulators 
of the pathway occurs. In the retina, host cells are protected 
from complement attack by complement factors such as 
CFH, a negative regulator of the complement alternative 
pathway. The RPE is the major local source of CFH at the 
retina/choroid interface. Thus, mutations or downregulation 
of CFH may increase the chance of RPE cells being attacked 
by activated complement systems. During the process of 
complement cascade activation, the small fragments of cleaved 
complement components C3a, C4a, and C5a, known as 
anaphylotoxins, stimulate inﬂ  ammation. C3a and in particular 
C5a, are potent inﬂ  ammatory factors, recruiting leucocytes 
from blood and stimulating secretion of cytokines that lead 
to ampliﬁ  cation of inﬂ  ammatory responses (Ember et al 
1994; Daffern et al 1995). In cultured RPE cells, treatment 
with C5a stimulates production of IL-8 (Fukuoka and Medof 
2001; Fukuoka et al 2003) and MCP-1 (Ambati et al 2003). 
Furthermore, C3a and C5a have been shown to be present in 
drusen (Johnson et al 2001; Ambati et al 2003), supporting the 
idea that RPE cells are constantly stimulated by the presence 
of C3a and C5a, which induce the release of inﬂ  ammatory 
mediators that subsequently cause further damage to retina 
in vivo. In addition, C3a and C5a are generated early in the 
course of laser-induced CNV and activation of C3aR or 
C5aR has been shown to be required for CNV formation 
(Nozaki et al 2006). Moreover, the alternative pathway has 
been suggested to play a central role in the CNV development 
in laser-induced murine model (Bora et al 2006). Taken 
together, these results suggest that complement-driven 
inﬂ  ammation is involved in the etiology of both dry and wet 
AMD as well as progression of dry to wet AMD.
Chronic infection
RPE cells can be infected in vitro with viruses and bacteria 
such as cytomegalovirus (Bodaghi et al 1999) and Bacillus 
cereus (Moyer et al 2008). The presence of viruses in RPE 
cells has also been demonstrated in patients (Henderly et al 
1988) and in animal models (Vann and Atherton 1991). 
Additionally, pathogen replication and toxin production 
can cause RPE death (Vann and Atherton 1991; Moyer et al 
2008). Evidence is accumulating that pathogen-induced Journal of Inﬂ  ammation Research 2008:1 56
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chronic infection may be a novel risk factor in the etiology of 
AMD. An increase in the prevalence of higher-titer antibody 
to Chlamydia pneumoniae was found more often in wet AMD 
than in dry AMD (Miller et al 2004). Subjects with high 
antibody titers had a threefold greater risk of progression 
than those with low antibody titers (Robman et al 2005). 
Pathogen infection may stimulate macrophage activation 
and entrapment between the choroid and RPE layer. Local 
release of cytokines from these macrophages in concert 
with cytokine release from overlying RPE cells might be 
involved in the manifestation of certain AMD phenotypes. 
This is supported by the observation that infection of 
macrophages and RPE cells with C. pneumoniae in vitro 
induces production of cytokines such as VEGF, IL-8, and 
MCP-1 (Kalayoglu et al 2005). Moreover, the risk of AMD 
progression was increased by about 12-fold when, in addition 
to having the CFH C-risk allele, subjects also presented with 
high antibodies titers to the bacterial pathogen C. pneumoniae 
(Baird et al 2008). These observations suggest that infection-
induced complement activation may participate in AMD 
progression, although a causal and functional tie between 
infection and AMD remains to be established.
Recruitment of inﬂ  ammatory cells
Injury to RPE cells caused by oxidative stress induced by 
a number of processes including ischemia, photooxidative 
damage, phagocytosis, and lipofuscin toxicity, serves as the 
critical seeding event in the initiation of drusen formation 
by secreting soluble cytokines that initiate recruitment of 
macrophages and DCs (Hageman et al 2001; Holtkamp 
et al 2001). Activated macrophages and DCs have been 
found to accumulate in the subretinal space of patients with 
AMD (Gupta et al 2003). However, it is unclear whether 
endogenous macrophages serve protective or destructive 
functions in these patients. Recruited macrophages have 
been shown to be required for clearance of drusen and 
other debris (Duvall and Tso 1985). While activated 
macrophages and DCs phagocytize RPE debris they also 
produce mediators that amplify local inﬂ  ammation (van der 
Schaft et al 1993; Hageman et al 2001; Penfold et al 2001). 
In support of a protective role for these cells, impairment 
in recruitment of macrophages leads to manifestations of 
atrophic AMD in CCL2 (MCP-1) knockout mice (Ambati 
et al 2003). Consistent with this, an age-dependent 
increase in the expression of CCL2 (MCP-1) in the RPE 
and in macrophage inﬁ  ltration is observed in the choroids 
of wild-type mice (Ambati et al 2003). Additionally, 
IL-10−/− mice have signiﬁ  cantly reduced laser-induced CNV 
formation with increased macrophage inﬁ  ltrates compared to 
wild type mice. Moreover, direct injection of macrophages 
into the eye of these IL-10−/− mice inhibits CNV (Apte et al 
2006). However, depletion of macrophages is also reported 
to inhibit experimental CNV (Espinosa-Heidmann et al 2003; 
Sakurai et al 2003). These ﬁ  ndings suggest that macrophages 
can serve in both pro- and anti-inﬂ  ammatory capacities, and 
that dysregulation of clearance functions may fuel disease 
progression.
DCs are powerful antigen-presenting cells that participate in 
the induction of immunity. Histochemical studies have revealed 
that DCs are present in drusen and are thus proposed to play 
a role in drusen biogenesis (Hageman et al 2001). According 
to this hypothesis, injured RPE cells recruit and activate DCs 
which sustain and amplify the local inﬂ  ammation by producing 
inflammatory mediators, activating complement system, 
and degrading extracellular matrix. The CX3C chemokine 
receptor 1 (CX3CR1) is expressed in retinal microglia cells 
(macrophages and DCs) and mediates migration and adhesion 
of these cells in response to its ligand. Interestingly, mice 
deﬁ  cient in CX3CR1 develop some cardinal features of AMD 
with accumulation of microglia cells in the subretinal space 
at the sites of retinal degeneration and CNV (Combadiere 
et al 2007). Manifestations of AMD-like retinal lesions are 
exacerbated by further knockdown of the chemokine, CCL2 
(MCP-1). AMD lesions are found in 6-week-old CX3CR1/
CCL2 double-deﬁ  cient mice while none of the single knockout 
mice develop retinal lesions at this age (Tuo et al 2007). 
This may be because of the retention of CX3CR1-deﬁ  cient 
microglia cells at the sites of cell and/or tissue injury leading to 
sustained inﬂ  ammation. In the laser-induced CNV model, DCs 
inﬁ  ltrate transiently into the lesion sites (Eter et al 2008; Nakai 
et al 2008) and intravenous DC transplantation augments CNV 
(Nakai et al 2008), supporting a contribution of DCs to the 
development of AMD.
Recent evidence suggests that lymphoid cells may also be 
involved in the development of experimental atrophic AMD. 
When RAG-deﬁ  cient mice lacking mature lymphocytes were 
challenged with MSA adducted with CEP, unlike wild-type 
mice they failed to produce antigen-speciﬁ  c antibodies and 
ﬁ  x C3 in Bruch’s membrane. Nor did these animals develop 
an AMD-like phenotype (Hollyﬁ  eld et al 2008).
Potential therapeutic approaches 
for atrophic AMD
Damage caused by oxidative stress and inﬂ  ammation lead 
to progressive loss of cell function and thus contributes to 
the development of atrophic AMD. Protecting RPE cells by Journal of Inﬂ  ammation Research 2008:1 57
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neutralizing ROS, promoting cell survival, and inhibiting 
inﬂ  ammatory responses could potentially delay the onset 
or progression of this disease. Discussed below are two 
treatment strategies: cytoprotection and anti-inﬂ  ammation 
therapy.
Cytoprotection
RPE cell death is believed to constitute the primary events in 
atrophic AMD and subsequent dysfunction and degeneration 
of photoreceptor cells lead to the loss of cone-mediated high 
resolution central and color vision. Thus, preservation of 
RPE and photoreceptor cells could help prevent progression 
of AMD.
ROS scavengers
Antioxidants have the capacity to alleviate or reduce the 
detrimental effects of ROS in response to a variety of 
stress stimuli. Extensive laboratory investigations have 
demonstrated the role of oxidative stress and the inhibitory 
effects of antioxidants on RPE cellular function (Choudhary 
et al 2005; Fernandez-Robredo et al 2005; Voloboueva 
et al 2005). Clinically, antioxidant supplements may delay 
the onset of AMD and progression to advanced AMD. The 
Age-related Eye Disease Study (AREDS) was comprised 
of 3640 participants who were randomized into cohorts 
receiving daily high-dose antioxidants (vitamin C 500 mg, 
vitamin E 400 IU, β-carotene 15 mg), or zinc (80 mg zinc 
oxide, 2 mg copric oxide), or antioxidants plus zinc or 
placebo (AREDS. 2001). With an average 6.5-year follow-
up, comparison with placebo showed a statistically signiﬁ  cant 
reduction in the development of advanced AMD in those 
patients receiving antioxidants plus zinc (AREDS. 2001). At 
5 years in the absence of supplementation of antioxidants plus 
zinc, the estimated probability of progression of participants 
with advanced AMD or vision loss due to nonadvanced AMD 
to advanced AMD in the second eye was 43%. The 5-year 
estimated probability of progression to advanced AMD in 
either eye with extensive intermediate drusen, large drusen, 
or noncentral geographic atrophy is 18% (AREDS 2001). 
Thus, people at risk of developing advanced AMD lowered 
this risk by about 25% when treated according to the AREDS 
recommendations. It has been estimated that if the 8 million 
people in the USA at risk of advanced AMD receive AREDS-
recommended supplements, 329, 000 of them would avoid 
developing advanced AMD during the next 5 years (Bressler 
et al 2003). In addition, dietary lutein/zeaxanthin intake has 
been shown to be inversely associated with the occurrence 
of geographic atrophy and large or extensive intermediate 
drusen (SanGiovanni et al 2007). Taken together these data 
demonstrate that dietary supplementation with antioxidants 
reduce the risk of progression of AMD. OT-551, a catalytic 
antioxidant with anti-inﬂ  ammatory activity has been shown 
to functionally and morphologically protect photoreceptor 
cells against acute light-induced damage in an animal model 
(Tanito et al 2007) and is currently being assessed in clinical 
trials in AMD patients with geographic atrophy (Table 1).
Induction of phase 2 antioxidant enzymes including SOD, 
catalase, glutamate cysteine ligase, and heme oxygenase-1 
by phase 2 enzyme inducers provides an alternative way to 
protect cells against ocular oxidative stress. High amounts of 
catalase (Tate et al 1995), SOD (Oliver and Newsome 1992), 
and glutathione (Newsome et al 1994; Beatty et al 2000) can 
efﬁ  ciently detoxify and remove ROS once they are generated 
in RPE cells. GSH synthesis can be induced in cultured RPE 
cells by a number of naturally occurring compounds that 
induce phase 2 detoxiﬁ  cation enzymes, including the rate-
limiting enzyme for GSH synthesis, glutamate cysteine ligase 
(Nelson et al 1999; Voloboueva et al 2005; Ha et al 2006; 
Qin et al 2006). RPE cells can be protected from peroxide-
induced damage by pre-treatment with a number of agents 
Table 1 Developing therapies for atrophic age-related macular degeneration
Compound Indications Company State of development Mechanism of activation
OT-551 Geographic atrophy Othera Phase 2 Antioxidants and 
anti-inﬂ  ammation
CNTF (NT-501) Geographic atrophy and 
retinitis pigmentosa
Neurotech Phase 2 Anti-apoptosis
JPE-1375 Geographic atrophy Jerini Pre-clinical testing C5aR antagonist
PMX-53 AMD and arthritis Arana Pre-clinical testing C5aR antagonist
POT-4 Geographic atrophy and 
inﬂ  ammatory ocular 
diseases
Potentia Phase 1 C3 inhibitor
Fenretinide Geographic atrophy Sirion Phase 2 Vitamin A receptor antagonistJournal of Inﬂ  ammation Research 2008:1 58
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that induce GSH synthesis including dimethylfumarate 
(Nelson et al 1999), 15-deoxy-Δ12,14-prostaglandin J2 (Qin 
et al 2006), (R)-α-lipoic acid (Voloboueva et al 2005), or 
zinc (Ha et al 2006). Sulforaphane, a potent inducer of phase 
2 antioxidant enzymes, has been demonstrated to protect RPE 
cells from photooxidative damage in vitro (Gao and Talalay 
2004; Tanito et al 2005; Zhou et al 2006) and in vivo (Tanito 
et al 2005). A single dose of oltipraze, another potent phase 
2 enzyme inducer, signiﬁ  cantly stimulated GSH level in 
lymphocytes isolated from human blood (Gupta et al 1995), 
and induced a four- to ﬁ  vefold increase in mRNA transcripts 
for glutamate cysteine ligase and quinone reductase in colon 
mucosa (O’Dwyer et al 1996). These ﬁ  ndings provide a 
strong rationale to test whether phase 2 enzyme inducers, 
such as sulforaphane and oltipraz, can elevate the antioxidant 
enzymes in the retina and whether they can prevent oxidative 
damage in humans at risk for AMD.
Antiapoptotic approaches
In addition to the maintenance of antioxidant capacity, RPE 
cells and photoreceptors can be persevered by stimulating 
cell survival signaling and/or inhibiting death pathways.
RPE cell survival
Cell viability is precisely regulated by the balanced expression 
of pro- and antiapoptotic factors such as the Bcl-2 family of 
proteins. As expected, ectopic expression of antiapoptotic 
proteins Bcl-2 renders RPE cells resistant to A2E-mediated 
toxicity (Sparrow and Cai 2001) whereas knockdown of 
Bcl-xL expression leads to RPE cell death (Zhang et al 2007). 
Neuroprotectin D1 (NPD1), a metabolite of DHA that is rich 
in the retina, has been shown to protect against RPE cell 
apoptosis induced by A2E, a byproduct of phototransduction 
(Mukherjee et al 2007), as well as hydrogen peroxide and 
tumor necrosis factor-α (Mukherjee et al 2004). NPD1 and 
DHA protect RPE cells via upregulation of antiapoptotic 
proteins and downregulation of pro-apoptotic proteins of Bcl-2 
family (Mukherjee et al 2004, 2007). Pigment epithelium-
derived factor (PEDF), secreted by RPE cells, is a trophic 
factor required for RPE cell function and survival under stress 
conditions. PEDF can protect RPE cells from oxidant-mediated 
barrier dysfunction (Tsao et al 2006) and death (Ho et al 2006). 
ERK activation and NPD1 production stimulated by PEDF 
appear to be involved in mediating PEDF’s cyto-protective 
effects (Tsao et al 2006; Mukherjee et al 2007). Interestingly, 
PEDF levels in RPE cells are signiﬁ  cantly reduced in AMD 
patients (Bhutto et al 2006). Thus, increases in PEDF levels 
could potentially delay the onset of RPE abnormalities and 
progression to RPE cell atrophy.
Photoreceptor cell survival
RPE cell death initiates the development of atrophic AMD. 
However, loss of vision is caused by the death of rod and 
cone photoreceptors. Thus, the preservation of macular 
photoreceptors is a valid anti-AMD strategy. Many trophic 
factors can support photoreceptor survival (LaVail et al 
1992; Steinberg 1994). Among them, PEDF and ciliary 
neurotrophic factor (CNTF) have demonstrated consistent 
photoreceptor protection. PEDF protects cultured retinal 
neurons from hydrogen peroxide injury (Cao et al 1999) 
and inhibits macrophage-driven inﬂ  ammation (Zamiri et al 
2006). In vivo, intravitreal injection or intraocular gene 
transfer of PEDF rescues photoreceptors from light-induced 
damage (Cao et al 2001; Imai et al 2005). Moreover, a PEDF 
(82–121) peptide is as effective as full-length PEDF in 
protecting retina from ischemia and longer protection can be 
achieved if delivered in poly(lactide-co-glycolide) (PLGA) 
nanospheres (Li et al 2006). Taken together with the RPE 
protective effects, these observations suggest that PEDF is 
a promising therapeutic treatment for AMD.
CNTF is another trophic factor that has reached clinical 
development for retinal degeneration (Sieving et al 2006). 
Injection or gene transfer of CNTF protects photoreceptor 
degeneration in animal models (LaVail et al 1998; Huang 
et al 2004). Delivery of CNTF by encapsulated cell-based 
technology reduces photoreceptor degeneration in animal 
model of retinitis pigmentosa (Tao et al 2002). This delivery 
system, which can deliver CNTF to the vitreous for at least 
1 year (Thanos et al 2004), is currently being evaluated 
clinically.
Anti-inﬂ  ammation therapy
Steroids
Clinical studies have indicated that corticosteroid, 
triamcinolone acetonide (TA), has the capacity to reduce 
the permeability of the outer blood–retinal barrier (Antoszyk 
et al 1993), promote resorption of subretinal exudation 
(Penfold et al 1995) and downregulate inﬂ  ammatory stimuli 
(Tanner et al 1998). After 18 months of treatment with TA 
in patients with exudative AMD, the rate of development of 
severe visual loss in treated patients was 30%, compared with 
55% for historical controls (Challa et al 1998). Anecortave 
acetate is another angiostatic steroid that might be clinically 
efﬁ  cacious for maintaining vision, preventing severe vision 
loss, and inhibiting subfoveal CNV lesion growth (Russell 
et al 2007). Anecortave acetate was approved for use in wet 
AMD in Australia in 2005 with approval pending in the US. 
A third steroid, Posurdex (dexamethasone implant) is in Journal of Inﬂ  ammation Research 2008:1 59
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phase III clinical trial for retinal vein occlusion and diabetic 
macular edema. Although no clinical data are available 
yet, the role of chronic inﬂ  ammation in atrophic AMD 
pathogenesis (Hageman et al 2001; Anderson et al 2002) 
has led to the consideration that atrophic AMD patients 
might be expected to beneﬁ  t from anti-inﬂ  ammatory therapy 
that attenuates the local inﬂ  ammation, thereby preventing 
progression of the disease.
Nonsteroidal anti-inﬂ  ammatory drug
Epidemiology and animal studies suggest that nonsteroidal 
anti-inﬂ  ammatory drugs (NSAIDs) can delay the onset and 
progression of Alzheimer’s disease (AD) (Townsend and 
Pratico 2005; McGeer and McGeer 2007). Amyloid-β (Aβ), 
a major trigger of AD pathogenesis, is present in drusen 
from retinas with AMD (Dentchev et al 2003). Owing to the 
compositional similarities between drusen and AD-associated 
plaques, atrophic AMD patients might be expected to beneﬁ  t 
from NSAID therapy that may attenuate local inﬂ  ammation 
(Mullins et al 2000; Luibl et al 2006). Consistent with this, 
accumulation of Aβ causes RPE atrophy and basal deposit 
formation, characteristic features of human AMD (Yoshida 
et al 2005). Moreover, the addition of Aβ to cultured 
RPE cells upregulates expression of VEGF (Yoshida et al 
2005; Ma et al 2007) and downregulates PEDF expression 
(Yoshida et al 2005). The anti-inﬂ  ammatory compounds 
eicosapentaenoic acid and astaxanthin have been shown 
to inhibit cytokine production, macrophage activation, and 
CNV formation in mice (Koto et al 2007; Izumi-Nagai et al 
2008). Consistent with these observations, the prevalence 
of AMD in rheumatoid arthritis patients with long term 
NSAID use is about 10-fold lower than in general populations 
of similar racial origin (McGeer and Sibley 2005). Thus, 
additional studies of the potential utility of NSAIDs for the 
treatment of AMD patients are warranted.
Complement pathway regulators
As discussed in the section III, certain CFH haplotypes are 
associated with increased frequency of AMD (Hageman 
et al 2005; Hughes et al 2006). In contrast, the L9H variant 
of CFB, which participates in the amplification of the 
complement alternative pathway, confers a signiﬁ  cantly 
reduced risk for AMD (Gold et al 2006). Conceivably, 
delivery of a protective variant of the CFH or CFB through 
gene therapy or as a biologic could block activation of the 
alternative pathway and serve as an anti-AMD strategy. 
Alternatively, as CFB and CFD are both serine proteases 
small-molecule, inhibitors of these proteins could be used 
to inhibit activation of the alternate pathway.
Reduction of the CFH-associated AMD may also be 
achieved by inhibiting targets downstream the point of 
conversion for all three complement pathways. JPE-1375 
and PMX53 are two small molecule peptidomimetic 
antagonists targeting the C5a receptor (Schnatbaum et al 
2006) and are in preclinical evaluation for AMD. POT-4 is 
a cyclic peptide capable of binding to human C3 and prevents 
its activation, resulting in broad and potent complement 
activation inhibition (Nilsson et al 1998). POT-4 is the ﬁ  rst 
complement inhibitor that has entered into a Phase I clinical 
trial for AMD (Table 1).
Other novel therapeutic approaches
Besides antioxidant and anti-inflammation therapies, 
other novel therapeutic approaches are currently under 
development for the treatment of atrophic AMD. Lipofuscin 
in RPE cells is an autoﬂ  uorescent lipid-retinoid aggregate 
derived from visual cycle retinoids in photoreceptor cells. 
The major component of lipofuscin is A2E, a product of 
condensation of two molecules of all-trans-retinal with one 
molecule of phosphatidylethanolamine (Sparrow et al 2003). 
Lipofuscin accumulation in RPE cells is the key feature of the 
aging retina (Sparrow and Boulton 2005). In vitro, A2E can 
inhibit lysosomal function, perturb cholesterol metabolism, 
cause light-induced oxidative stress to RPE cells as well as 
activate the complement pathway (Bergmann et al 2004; 
Zhou et al 2006; Lakkaraju et al 2007). Therefore, reducing 
A2E accumulation in RPE cells by inhibiting the visual cycle 
could lead to delay in visual loss in the patients with atrophic 
AMD. Fenretinide, a synthetic nontoxic retinoid, competes 
with all-trans-retinol binding to retinol binding protein, 
thereby reducing ocular all-trans-retinol uptake and inhibiting 
the visual cycle (Radu et al 2005). Thus, administration of 
fenretinide effectively blocks A2E production and lipofuscin 
accumulation (Radu et al 2005). Fenretinide is currently in 
clinical trials to evaluate its efﬁ  cacy on AMD patients with 
geographic atrophy.
Issues and challenges
Etiology of atrophic AMD
Despite an increase in our understanding of the immunologi-
cal factors involved in atrophic AMD, this knowledge has 
yet to be translated into new treatments. One possible reason 
for this is our lack of understanding of disease chronicity, 
and the causative rather than risk factors that contribute to 
disease. Do drusen materials in AMD represent an abnormal 
or normal accumulation of metabolic debris? Why do soft 
drusen appear in macular area? What speciﬁ  c factors lead Journal of Inﬂ  ammation Research 2008:1 60
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to atrophy of the RPE and photoreceptors? The answers 
to these questions could one day be exploited to provide 
ideas for novel therapies. Another issue is the variability in 
disease characteristics at different stages of progression. As 
our understanding of the natural history of atrophic AMD 
grows, eligibility criteria for clinical trials might be tailored 
depending on the mechanism of action of a particular drug 
candidate.
Animal models
A variety of animal models have been developed to 
investigate the pathogenesis of atrophic AMD and test 
therapeutic compounds to ameliorate the pathology. 
Inflammatory models of AMD have been generated to 
elucidate the role of inﬂ  ammation in the etiology of AMD. 
One such model can be induced by immunization of mice 
with MSA adducted with CEP, an oxidation fragment of 
DHA (Hollyﬁ  eld et al 2008). Mice challenged with the CEP 
produce antigen-speciﬁ  c antibodies, develop drusen under 
the RPE and lesions mimicking atrophic AMD. Moreover, 
macrophages are observed in the interphotoreceptor matrix 
in these mice (Hollyfield et al 2008). As complement 
deposition is also observed below the RPE in this model 
the phenotype appears to be driven by activation of this 
pathway. Other inﬂ  ammatory models include mice with 
knockouts of the chemokine receptor CX3CR1 with CCL2 
(MCP-1) or CCR2 in combination with its ligand, CCL2 as 
well (Ambati et al 2003; Combadiere et al 2007; Tuo et al 
2007). These knockout mice display many of the features of 
AMD including the accumulation of lipofuscin, A2E, drusen 
as well as photoreceptor atrophy and CNV. Additionally, in 
the case of the CX3CR1 knockouts, subretinal accumulation 
of microglial cells was observed (Combadiere et al 2007; 
Tuo et al 2007).
There are also a number of noninﬂ  ammatory models that 
have been developed. The sodium iodate model involves the 
selective induction of RPE necrosis followed by photoreceptor 
degeneration in a pattern resembling gyrate atrophy of the 
choroid and retina (Kiuchi et al 2002). The mcd/mcd mouse 
was generated using a dominant negative form of Cathepsin 
D which is required for RPE phagocytosis of shed POS 
membrane discs (Rakoczy et al 2002). This transgenic mouse 
model manifests features of AMD including lipofuscin 
accumulation and both photoreceptor and RPE atrophy. 
The SOD1-deﬁ  cient mouse represents a novel model of 
ROS-mediated retinal degeneration, which similarly displays 
features of AMD such as drusen, RPE atrophy, and CNV 
(Imamura et al 2006; Hashizume et al 2008).
The extrapolation of experimental data obtained from 
animal studies to explain the in vivo pathological conditions 
must be done with caution. First, the mouse retina does not 
contain a specialized macula, thus, a murine model is not 
an exact replica of the human condition. Moreover, the 
components of drusen described in many animal models have 
not been molecularly characterized to conﬁ  rm a similarity 
with human drusen. In this regard, some progress has been 
made to identify a nonhuman primate model of AMD. 
A cynomolgus monkey pedigree has been identiﬁ  ed that 
develops early onset macular degeneration (Umeda et al 
2005). Interestingly, many components in the drusen of these 
animals are comparable to those found in human drusen 
(Umeda et al 2005). Furthermore, the loss of ultrastructure 
and function as well as progression of the disease is similar 
to that observed in humans (Dawson et al 2008).
AMD is a multi-factor disease; however, the available 
animal models only evaluate the contributions of one or at 
most two risk factors. Thus this limits the utility of these 
animal models of AMD for drug testing. Frequently, in 
the case of genetically modiﬁ  ed animals the penetrance 
of the observed phenotype is not complete. Moreover, 
the appearance of many of the AMD-like features occurs 
over a protracted period. Thus, a large number of animals 
and a prolonged treatment regimen would be required to 
test potential drug candidates. Efforts to accelerate the 
manifestation of the measurable features of these models 
are ongoing. Crossing various transgenic and knockout 
mice may accelerate the course of the disease. Alternatively, 
modiﬁ  cation of environmental factors such as diet or the 
addition of other risk factors could similarly hasten disease 
progression. For example, the addition of paraquat to 
SOD1-defﬁ  cient mice has been shown to result in changes in 
electroretinography measurements within two weeks (Dong 
et al 2006). These efforts have the potential to enhance the 
utility of these models for drug development signiﬁ  cantly.
Conclusions and future studies
Currently, most treatments for AMD such as laser photo-
coagulation, photodynamic therapy, surgery, and anti-VEGF 
antibodies beneﬁ  t patients in advanced stages of the disease. 
The progressive nature of atrophic AMD and the extensive cell 
damage in affected individuals at the time of diagnosis indicates 
that the future of atrophic AMD therapeutics is in the prevention of 
progression of the disease. Any drug for disease prevention needs 
to fulﬁ  ll two crucial requirements. First, the drug should target 
a key mechanism responsible for the initiation or progression of 
the disease process. Second, the drug should have minimal side Journal of Inﬂ  ammation Research 2008:1 61
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effects and be tolerated for extended periods. To date no such 
therapy is available for atrophic AMD. Thus, educating people 
about the risk factors associated with this disease such as smoking 
and diet is an important consideration at present. The development 
of pharmacological approaches to prevent onset or progression 
of AMD faces signiﬁ  cant hurdles including a lack of understand-
ing of the molecular mechanisms underlying the disease and 
the paucity of experimental models for testing potential drugs. 
Although a causal relationship based upon mechanistic studies 
of oxidative injury and inﬂ  ammation has not been completely 
established, the cumulative evidence presented in this review 
suggests a strong correlation between oxidative stress, inﬂ  ammation 
and AMD. This represents a signiﬁ  cant step towards the goal of 
identifying more effective treatments for this disease.
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